Cat. No.: HY-N0437

Copy Link Print Information

Progesterone

(Synonyms: Pregn-4-ene-3,20-dione)

34 Cited Publications

Customer Review

Based on 34 publication(s) in Google Scholar

Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.

For research use only. We do not sell to patients.

Purity: 99.79%
CAS No.: 57-83-0
Formula: C₂₁H₃₀O₂
Molecular Weight:314.46

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Progesterone Chemical Structure

CAS No.: 57-83-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Induced Disease Models
Chemical Information
Publications (34)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Breast cancer cell line	EC₅₀	18.7 μM Compound: Progesterone	Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Breast cancer cell line	EC₅₀	22.3 μM Compound: Progesterone	Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Cancer cell lines	IC₅₀	27.4 μM Compound: Progesterone	Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells. Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.	[PMID: 11784143]
Cancer cell lines	IC₅₀	36.4 μM Compound: Progesterone	Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells. Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.	[PMID: 11784143]
CHO	EC₅₀	2.77 μM Compound: 44	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
CV-1	EC₅₀	2.9 nM Compound: prog	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	[PMID: 10212133]
CV-1	EC₅₀	2.9 nM Compound: Progesterone	Human progesterone receptor (hPR) agonist activity expressed in CV-1 cells Human progesterone receptor (hPR) agonist activity expressed in CV-1 cells	[PMID: 10743938]
CV-1	EC₅₀	2.9 nM Compound: Progesterone	Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells	[PMID: 12781197]
CV-1	EC₅₀	2.9 nM Compound: progesterone	Agonistic activity against human progesterone receptor in CV-1 cells Agonistic activity against human progesterone receptor in CV-1 cells	[PMID: 12954062]
CV-1	EC₅₀	15.2 nM Compound: Progesterone	Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	>10000 nM Compound: Progesterone	Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	30 nM Compound: progesterone	Inhibition of 10e-9 M aldosterone activity in CV-1 cells expressing mineralocorticoid receptor Inhibition of 10e-9 M aldosterone activity in CV-1 cells expressing mineralocorticoid receptor	[PMID: 8709117]
CV-1	EC₅₀	2.9 nM Compound: Progesterone	Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay. Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	<10000 nM Compound: Progesterone	Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	14 nM Compound: Progesterone	Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	37 nM Compound: Progesterone	Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	<10000 nM Compound: Progesterone	Antagonistic activity was determined in Human estrogen receptor(hER) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human estrogen receptor(hER) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	>1000 nM Compound: Progesterone	Antagonistic activity was determined in Human glucocorticoid receptor(hGR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human glucocorticoid receptor(hGR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	EC₅₀	2.89 nM Compound: Progesterone	Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells. Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells.	[PMID: 9464361]
CV-1	EC₅₀	1.5 nM Compound: progesterone	Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells	[PMID: 9667968]
CV-1	EC₅₀	2.9 nM Compound: progesterone	Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell	[PMID: 9784110]
CV-1	IC₅₀	>10000 nM Compound: progesterone	inhibitory concentration was determined from full dose response curves ranging from 10 E -12 to 10 E -5M in CV-1 cell inhibitory concentration was determined from full dose response curves ranging from 10 E -12 to 10 E -5M in CV-1 cell	[PMID: 9784110]
CV-1	IC₅₀	14 nM Compound: progesterone	Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	37 nM Compound: progesterone	Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	>1000 nM Compound: progesterone	Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	>10000 nM Compound: progesterone	IC50 determined against human estrogen receptor in CV-1 cells IC50 determined against human estrogen receptor in CV-1 cells	[PMID: 9784110]
HEK293	IC₅₀	26.7 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells	[PMID: 12110607]
HEK293	IC₅₀	3.05 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells	[PMID: 12110607]
HEK293	IC₅₀	4.28 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells	[PMID: 12110607]
HEK293	EC₅₀	2 nM Compound: prog	Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
HeLa	IC₅₀	>50 μg/mL Compound: 4	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24021891]
HRPE	IC₅₀	1.6 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells	[PMID: 9830022]
HRPE	IC₅₀	10.5 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells	[PMID: 9830022]
K562/R7	IC₅₀	10.6 μM Compound: progesterone	Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay	[PMID: 25634041]
LNCaP	IC₅₀	13.7 nM Compound: Progesterone	Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay	[PMID: 30925341]
NIH-3T3-G185	IC₅₀	192.2 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	88.1 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	96.2 μM Compound: Progesterone	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
T47D	EC₅₀	1.8 nM Compound: prog	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	[PMID: 10212133]
T47D	EC₅₀	1.8 nM Compound: Progesterone	Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line	[PMID: 10743938]
T47D	EC₅₀	0.92 nM Compound: P4	Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line	[PMID: 11859003]
T47D	IC₅₀	3.5 nM Compound: P4	Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells	[PMID: 11859003]
T47D	EC₅₀	0.9 nM Compound: P4 (Progesterone)	Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line. Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line.	[PMID: 12657271]
T47D	EC₅₀	1.8 nM Compound: progesterone	Agonistic activity against human progesterone receptor in T47D breast cancer cells Agonistic activity against human progesterone receptor in T47D breast cancer cells	[PMID: 12954062]
T47D	IC₅₀	3.4 nM Compound: P4 (Progesterone)	Displacement of [3H]progesterone at progesterone receptor of T47D cells Displacement of [3H]progesterone at progesterone receptor of T47D cells	[PMID: 15081005]
T47D	EC₅₀	2.2 nM Compound: progesterone	Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity	[PMID: 18553958]
T47D	EC₅₀	0.9 nM Compound: 1	Activity at progesterone receptor assessed as alkaline phosphatase activity in human T47D cells Activity at progesterone receptor assessed as alkaline phosphatase activity in human T47D cells	[PMID: 18722119]
T47D	EC₅₀	0.1 nM Compound: P4	Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay	[PMID: 19863083]

In Vivo

Animal Model:

Adult female mice (7-13 wk, 18-28 g)^[4]
Dosage:

1 mg
Administration:

Injections; three consecutive daily
Result:

Stimulated vessel maturation in the mouse endometrium.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Progesterone can be used to create melasma models^[6].

Induction of Chloasma^[6]

Background

Progesterone increases the pigmentation and body weight. The body weight gain was believed to be due to sodium and fluid retention, which may further affect the intracellular pH of melanosomes, which synthesize melanin, in turn, leading to melanin production because tyrosinase activity is linked to the intracellular pH environment^[7].

Specific Modeling Methods

Mice: 6-8 weeks, female C57BL/6J mice
Administration: 15 mg/kg; Injected intramuscularly, daily for 30 days

Note

Selected 3*3 cm² area on the back of mice, shaved the hair, and then irradiated with UVB (λ=312 nm, 2 h/day).

Modeling Indicators

Phenotypic changes: cutaneous tissue injury, scab format, skin got blacker. Tissue changes: hair follicles necrosis, fibrous tissue hyperplasia, epidermal melanocyte enrichment. Molecular changes: p-JNK /JNK, p-P38MAPK/P38MAPK ↑.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 57-83-0
Appearance Solid
Molecular Weight 314.46
Formula C₂₁H₃₀O₂
Color White to off-white
SMILES

CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
Synonyms

Pregn-4-ene-3,20-dione
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (34)

All WBIPRT-PCRIHCIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Metab

Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury. [Abstract]

2024 Nov 5;36(11):2402-2418.e10. PMID: 39389061
Nat Commun

Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors. [Abstract]

2024 Oct 8;15(1):8708. PMID: 39379362

Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]

mIL1β secretion in THP-1 cells expressed with Myc-tagged E of indicated coronaviruses in the presence of 10 μM Progesterone for 4 h.

Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]

Co-IP using HEK293T cells with TMED10-V5 and Myc-E-MHV in the absence or presence of 10 μM Progesterone.

Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]

Progesterone (1 mg/kg; intraperitoneal injection). IL6 mRNA levels in indicated tissues were analyzed.

Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]

Progesterone (1 mg/kg; intraperitoneal injection). Lung inflammation was analyzed by H&E staining.

Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]

Progesterone (1 mg/kg; intraperitoneal injection). Quantitative analysis of the area of inflammation was performed.
Adv Sci (Weinh)

Depletion of Sorcs3 Activates Totipotency in Mouse Embryonic Stem Cells by Modulating Key Signaling Pathways. [Abstract]

2025 Nov 3:e09151. PMID: 41178446
Adv Sci (Weinh)

Capture of Totipotency in Mouse Embryonic Stem Cells in the Absence of Pdzk1. [Abstract]

2024 Dec 4:e2408852. PMID: 39630006
Nat Chem Biol

Structures of the ADGRG2-Gs complex in apo and ligand-bound forms. [Abstract]

2022 Nov;18(11):1196-1203. PMID: 35982227
Biosens Bioelectron

Split aptamer regulated CRISPR/Cas12a biosensor for 17β-estradiol through a gap-enhanced Raman tags based lateral ﬂow strategy. [Abstract]

2022 Nov 1:215:114548. PMID: 35870335
Diabetologia

Phosphodiesterase ENPP2, which is co-upregulated in obese and pregnant mice, is essential for islet beta cell compensation during obesity. [Abstract]

2025 Dec 26. PMID: 41454014
Proc Natl Acad Sci U S A

Progesterone activates GPR126 to promote breast cancer development via the Gi pathway. [Abstract]

2022 Apr 12;119(15):e2117004119. PMID: 35394864
Int J Biol Macromol

Antimicrobial peptide SCY2 with its interacting proteins Scyreprocin mediate the innate immune defense of Scylla paramamosain against Pseudomonas putida infection. [Abstract]

2025 Dec 21;338(Pt 2):149596. PMID: 41435952
Acta Pharmacol Sin

Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays. [Abstract]

2022 Sep;43(9):2429-2438. PMID: 35110698
Chemosphere

Early pregnancy exposure to Microcystin-LR compromises endometrial decidualization in mice via the PI3K/AKT/FOXO1 signaling pathway. [Abstract]

2024 Oct:366:143466. PMID: 39369752
Emerg Contam

2026 Feb 23.
J Med Chem

Discovery of Novel Nonsteroidal SGRMs of Sulfonamide-2-Oxo-Tetrahydroquinoline Derivatives by Carbonyl Migration. [Abstract]

2026 Jan 22;69(2):1507-1529. PMID: 41490153
J Med Chem

Discovery and Optimization of N-Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators. [Abstract]

2022 Dec 8;65(23):15710-15724. PMID: 36399795
NPJ Regen Med

Macrophages maintain mammary stem cell activity and mammary homeostasis via TNF-α-PI3K-Cdk1/Cyclin B1 axis. [Abstract]

2023 May 2;8(1):23. PMID: 37130846
J Anim Sci Biotechnol

Cysteine dioxygenase and taurine are essential for embryo implantation by involving in E2-ERα and P4-PR signaling in mouse. [Abstract]

2023 Jan 5;14(1):6. PMID: 36604722
Hum Reprod

Hypomethylation of the GSTM1 promoter is associated with ovarian endometriosis. [Abstract]

2019 May 1;34(5):804-812. PMID: 30989213
Eur J Med Chem

Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation. [Abstract]

2022 Jul 5:237:114382. PMID: 35483323
Eur J Med Chem

Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. [Abstract]

2019 Jun 1:171:265-281. PMID: 30925341
Int Immunopharmacol

Quercetin alleviates imatinib-induced premature ovarian insufficiency by regulating mitophagy via the ROS/JNK/c-JUN pathway. [Abstract]

2026 Apr 15:175:116405. PMID: 41722539
Neuropharmacology

Dyadic social interaction paradigm reveals selective role of ovarian estrogen in the caring behavior and socially transferred pain in female mice. [Abstract]

2024 Sep 5:110138. PMID: 39244013
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Sci Rep

Comparative analysis of organoid, air-liquid interface, and direct infection models for studying pathogen-host interactions in endometrial tissue. [Abstract]

2025 Mar 12;15(1):8531. PMID: 40075187
Sci Rep

Dynamic change of estrogen and progesterone metabolites in human urine during pregnancy. [Abstract]

2025 Mar 11;15(1):8409. PMID: 40069295
Cell Signal

Inhibitory effects of Eplerenone on angiogenesis via modulating SGK1/TGF-β pathway in contralateral kidney of CKD pregnancy rats. [Abstract]

2024 Aug 13:111346. PMID: 39147296
Mol Cell Endocrinol

Extended steroid profiling in H295R cells provides deeper insight into chemical-induced disturbances of steroidogenesis: Exemplified by prochloraz and anabolic steroids. [Abstract]

2023 Jun 15:570:111929. PMID: 37037411
Curr Issues Mol Biol

Thymol Mitigates Oxidative Stress-Induced Ovarian Aging and Restores Steroidogenesis via the JAK1-STAT3 Pathway. [Abstract]

2025 Nov 2;47(11):910. PMID: 41296414
J Pharmacol Sci

Activation of σ-1 receptor mitigates estrogen withdrawal-induced anxiety/depressive-like behavior in mice via restoration of GABA/glutamate signaling and neuroplasticity in the hippocampus. [Abstract]

2024 Apr;154(4):236-245. PMID: 38485341
J Orthop Surg Res

Integrated analysis of bioinformatics, mendelian randomization, and experimental validation reveals novel diagnostic and therapeutic targets for osteoarthritis: progesterone as a potential therapeutic agent. [Abstract]

2025 Jan 23;20(1):85. PMID: 39849508
Exp Ther Med

Tilianin attenuates MPP+-induced oxidative stress and apoptosis of dopaminergic neurons in a cellular model of Parkinson's disease. [Abstract]

2022 Apr;23(4):293. PMID: 35340873
J Neurosci Methods

Insulin and heparin-binding epidermal growth factor-like growth factor synergistically promote astrocyte survival and proliferation in serum-free medium. [Abstract]

2018 Sep 1:307:240-247. PMID: 29890195
SSRN

2025 Apr 5.
Patent

US20200129476A1
Patent

US20200078369A1

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (159.00 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1801 mL

15.9003 mL

31.8005 mL

5 mM

0.6360 mL

3.1801 mL

6.3601 mL

10 mM

0.3180 mL

1.5900 mL

3.1801 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 10 mg/mL (31.80 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 20 mg/mL (63.60 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Schindler AE, et al. Classification and pharmacology of progestins. Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16. [Content Brief]

[2]. Zava DT, et al. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998 Mar;217(3):369-78. [Content Brief]

[3]. Komesaroff PA, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001 Jun;4(2):144-50. [Content Brief]

[4]. Girling JE, et al. Progesterone, but not estrogen, stimulates vessel maturation in the mouse endometrium. Endocrinology. 2007 Nov;148(11):5433-41. Epub 2007 Aug 9. [Content Brief]

[5]. Wong R, et al. Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy. J Pharm Pharmacol. 2012 Nov;64(11):1614-20. [Content Brief]

[6]. Wang JY, et al. Licorice zinc suppresses melanogenesis via inhibiting the activation of P38MAPK and JNK signaling pathway in C57BL/6J mice skin. Acta Cir Bras. 2022 Dec 19;37(10):e371002. [Content Brief]

[7]. Hisayoshi NoRIMOTO, et al. Effects of keishibukuryoganryokayokuinin (gui-zhi-fu-ling-wanliao-jia-yiyiren) on the Epidermal Pigment Cells from DBA/2 Mice Exposed to Ultraviolet B (UVB) and/or Progesterone. The pharmaceutical Society of Japan. 2011, 131(11):1613-1619.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1801 mL	15.9003 mL	31.8005 mL	79.5014 mL
	5 mM	0.6360 mL	3.1801 mL	6.3601 mL	15.9003 mL
	10 mM	0.3180 mL	1.5900 mL	3.1801 mL	7.9501 mL
	15 mM	0.2120 mL	1.0600 mL	2.1200 mL	5.3001 mL
	20 mM	0.1590 mL	0.7950 mL	1.5900 mL	3.9751 mL
	25 mM	0.1272 mL	0.6360 mL	1.2720 mL	3.1801 mL
	30 mM	0.1060 mL	0.5300 mL	1.0600 mL	2.6500 mL
	40 mM	0.0795 mL	0.3975 mL	0.7950 mL	1.9875 mL
	50 mM	0.0636 mL	0.3180 mL	0.6360 mL	1.5900 mL
	60 mM	0.0530 mL	0.2650 mL	0.5300 mL	1.3250 mL
	80 mM	0.0398 mL	0.1988 mL	0.3975 mL	0.9938 mL
	100 mM	0.0318 mL	0.1590 mL	0.3180 mL	0.7950 mL

Keywords

Progesterone

34 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Progesterone

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Food-Sourced Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Human Hormone Compound Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Animal Drug Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Cardiotoxic Compound Library

Lipid Metabolite Compound Library

Mongolian Medicine Compound Library

Steroid Hormones Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Progesterone

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (34)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Progesterone Related Classifications

Cat. No.: HY-N0437